HCPLive Network

Diabetic Retinopathy Severity Linked to Cardiovascular Outcome

 
THURSDAY, Jan. 24 (HealthDay News) -- For individuals with type 2 diabetes, incident cardiovascular outcomes are determined not only by the severity of diabetic retinopathy but also by its progression, according to research published online Dec. 13 in Diabetes Care.

Hertzel C. Gerstein, M.D., of McMaster University in Hamilton, Canada, and colleagues examined the correlation between retinopathy, four-year progression, and cardiovascular outcomes (cardiovascular death, nonfatal myocardial infarction, or stroke) using data from 3,433 participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and ACCORD Eye Study, who had baseline retinal photographs.

The researchers found that the adjusted hazard ratio for cardiovascular outcome increased from 1.49 for mild retinopathy to 2.35 for severe retinopathy, compared with no retinopathy. For a subset of 2,856 participants evaluated for disease progression at four years, for each category of change in retinopathy severity, the risk of the primary outcome increased by 38 percent. The correlation between progression and cardiovascular outcomes was no longer significant after adjustment for the baseline and follow-up levels of glycated hemoglobin, systolic blood pressure, and lipids either individually or together.

"The clear link between progression of retinal disease and cardiovascular disease suggests that these two serious consequences of diabetes may share an underlying pathophysiological basis," the authors write.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Moderate alcohol consumption may benefit diabetics, but puts them at risk of deterioration of visual acuity unrelated to typical diabetic eye disease.
A 36-year-old Hispanic man was diagnosed with type 1 diabetes in 1987 and dyslipidemia in 2001.
Clinicians should consider a patient’s risk of hypoglycemia, the duration of time with the disease, age, comorbidities, vascular complications, and other factors when setting treatment goals.
Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.
For patients with type 2 diabetes, treatment with the dipeptidyl peptidase 4 inhibitors saxagliptin or alogliptin is not associated with improvements in cardiovascular risk, according to two studies published online Sept. 2 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 31 to Sept. 4 in Amsterdam.
It's a delicate balance that keeps retinal neovascularization under control and vascular endothelial growth factor seems to be the bad guy in the relationship.
For patients with type 2 diabetes, the severity of diabetic retinopathy (DR) is inversely linked to cognitive impairment.
More Reading